NTC
SAGE

NF Trinity Capital’s Sage Therapeutics SAGE Stock Holding History

NF Trinity Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3.07M Sell
19,313
-13,193
-41% -$1.91M 0.49% 30
2018
Q4 		$3.11M Hold
32,506
– – 0.51% 37
2018
Q3 		$4.59M Hold
32,506
– – 0.61% 39
2018
Q2 		$5.09M Buy
+32,506
New +$5.1M 0.7% 36

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

NF Trinity Capital's SAGE Position: Q1 2019 in Review

NF Trinity Capital reduced its Sage Therapeutics (SAGE) stake by 41% in Q1 2019, selling an estimated $1.91M and leaving 19,313 shares worth $3.07M. The position accounts for 0.49% of the portfolio, ranked #30.

NF Trinity Capital first reported a position in SAGE in Q2 2018 and has held it in 4 quarters since. The position peaked at $5.09M in Q2 2018. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • NF Trinity Capital held 19,313 shares of Sage Therapeutics worth $3.07M as of Q1 2019.
  • NF Trinity Capital sold 13,193 Sage Therapeutics shares in Q1 2019, an estimated $1.91M.
  • Sage Therapeutics made up 0.49% of NF Trinity Capital's portfolio in Q1 2019, its #30 holding.
  • NF Trinity Capital first reported a position in Sage Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • NF Trinity Capital's Sage Therapeutics position peaked at $5.09M in Q2 2018.
  • 267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.